-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 9 day(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
Micro abstract24-hour urine protein measurement is cumbersome and time consuming. It is standard part of diagnosis and monitoring of patients with monoclonal plasma cell disorders. We have carried out a prospective study comparing 24-hour urine protein and Spot urine protein measurements in Multiple Myeloma patients showing a good correlation between them. Spot urine protein measurement is an easier and reliable alternative to 24-hour urine protein measurement.
Categories: General Medicine News, Hem/OncsTweet-
Spot Urine Protein/Creatinine Ratio as an Alternative to 24-Hour Urine Collection for Measuring Proteinuria in Patients With Multiple Myeloma: A Prospective Study - https://t.co/iPvnKw6yvo #mmsm #bmtsm @JHillengass
-
-
Mashup Score: 22Real-World Safety and Tolerability of Rapid, 30-minutes, Intravenous Isatuximab in Patients with Multiple Myeloma. - 20 day(s) ago
Isatuximab-based combinations are widely used to treat patients with relapsed or refractory multiple myeloma, and will soon become part of the standard first-line therapies in transplant-eligible and transplant-ineligible newly diagnosed patients. Isatuximab is currently approved for intravenous fixed volume (250 ml) administration, with a maximum infusion rate of 200 ml/h and at least 75 minutes required for one administration. A recent clinical trial suggested the safety of a faster, 30-minute administration of isatuximab.
Categories: General Medicine News, Partners & KOLsTweet-
Nice to see in CLML - great work by our 🇨🇦 colleagues Kotb et al! After 2 cycles of isatuximab in #MMsm, move to 30-min infusions. No montelukast needed, albeit they did keep dex. 30 < 75 min, so less time toxicity for pts and more time for nurses! https://t.co/NiAUENhbCX https://t.co/8CzXDBbc8g
-
-
Mashup Score: 15
Lenalidomide, an immunomodulatory drug (IMiD), is considered a key component of standard of care for the treatment of patients with multiple myeloma (MM).1 The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines recommend lenalidomide-based triplet regimens (eg, carfilzomib-lenalidomide-dexamethasone, daratumumab-lenalidomide-dexamethasone, bortezomib-lenalidomide-dexamethasone, and ixazomib-lenalidomide-dexamethasone) for the initial treatment of patients with MM, including transplant-eligible and -ineligible patients.
Categories: General Medicine News, Hem/OncsTweet-
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1-3 Prior Lines: SEER-Medicare Database - Clinical Lymphoma, Myeloma and Leukemia https://t.co/T1bJcpmdQ9
-
-
Mashup Score: 0Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial - 1 month(s) ago
Micro-AbstractIn patients with newly diagnosed lymphoma, low bone mineral density (BMD) is common at diagnosis and worsens with therapy. Our randomized phase III trial demonstrates that 2 doses of zoledronic acid (ZA) and supplementation with calcium and vitamin D effectively prevent further bone loss.
Categories: General Medicine News, Hem/OncsTweet-
Zoledronic Acid for Prevention of Bone Loss in Lymphoma [12/29/12] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth - Clinical Practice Points: 1) Incr risk low BMD in ND & incr risk on Tx, 2) 2 doses ZA stabilize BMD, 3) Screening
-
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 1 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet-
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/IBFVjp7ytJ
-
-
Mashup Score: 0Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial - 1 month(s) ago
Micro-AbstractIn patients with newly diagnosed lymphoma, low bone mineral density (BMD) is common at diagnosis and worsens with therapy. Our randomized phase III trial demonstrates that 2 doses of zoledronic acid (ZA) and supplementation with calcium and vitamin D effectively prevent further bone loss.
Categories: General Medicine News, Hem/OncsTweet-
Zoledronic Acid for Prevention of Bone Loss in Lymphoma [12/29/12] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth - Clinical Practice Points: 1) Incr risk low BMD in ND & incr risk on Tx, 2) 2 doses ZA stabilize BMD, 3) Screening
-
-
Mashup Score: 20Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy - 2 month(s) ago
MicroabstractMultiple myeloma involving the central nervous system (CNS-MM) has a poor prognosis. This retrospective study evaluated outcomes of 45 patients treated with CNS-directed radiation therapy. Six of these patients had survival ranging from 11.2 to 52.2 months from CNS-MM diagnosis. Thus, aggressive multimodality therapy shows promise in achieving durable CNS control and longer-term survival in a small subset of patients.
Categories: General Medicine News, Hem/OncsTweet-
Outcome of Patients With CNS Multiple Myeloma Treated With CNS-Directed XRT. N=45, median OS from dx: 3.7 months. In 21 evaluable patients for response, CR 66.7%, median OS 7.3 months #mmsm @BouthainaDabaja @PennyFangMD #mmsm @MDAndersonNews https://t.co/2fEU4Doglv
-
-
Mashup Score: 1Vaccination in Multiple Myeloma: Review of Current Literature - 3 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: General Medicine News, Hem/OncsTweet-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu et al. @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc https://t.co/01ZiAi6V2l
-
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 3 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet-
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/IBFVjp7ytJ
-
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/IBFVjp7ytJ